Fleebs-Logo
Details werden geladen...

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026 | The Manila Times

Rapid oral presentation to highlight overall survival data from the DENALI Part 1b study of azenosertib SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced two presentations at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.

Ähnliche Seiten

https://www.manilatimes.net/2026/07/17/tmt-newswire/globenewswire/immatics-announces-upcoming-presentations-across-its-prame-franchise-at-esmo-congress-2026/2386671

Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026 | The Manila Times

https://www.manilatimes.net/2026/07/17/tmt-newswire/globenewswire/immatics-announces-upcoming-presentations-across-its-prame-franchise-at-esmo-congress-2026/2386671
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting/2349722

Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting | The Manila Times

https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting/2349722
https://www.manilatimes.net/2026/06/25/tmt-newswire/globenewswire/revolution-medicines-to-present-clinical-data-from-rason-inhibitor-combination-trials-in-pancreatic-cancer-at-esmo-gastrointestinal-cancers-congress-2026/2372431

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 | The Manila Times

https://www.manilatimes.net/2026/06/25/tmt-newswire/globenewswire/revolution-medicines-to-present-clinical-data-from-rason-inhibitor-combination-trials-in-pancreatic-cancer-at-esmo-gastrointestinal-cancers-congress-2026/2372431
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/genmab-to-highlight-advances-across-its-oncology-portfolio-at-the-2026-american-society-of-clinical-oncology-asco-annual-meeting-and-the-european-hematology-association-eha-2026-congress/2349701

Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress | The ...

https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/genmab-to-highlight-advances-across-its-oncology-portfolio-at-the-2026-american-society-of-clinical-oncology-asco-annual-meeting-and-the-european-hematology-association-eha-2026-congress/2349701
https://www.manilatimes.net/2026/07/17/tmt-newswire/globenewswire/compass-therapeutics-announces-tovecimig-data-accepted-for-an-oral-presentation-at-the-esmo-congress-2026/2386688

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026 | The Manila Times

https://www.manilatimes.net/2026/07/17/tmt-newswire/globenewswire/compass-therapeutics-announces-tovecimig-data-accepted-for-an-oral-presentation-at-the-esmo-congress-2026/2386688
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/zentalis-pharmaceuticals-to-present-phase-1b-muir-trial-data-showing-encouraging-clinical-activity-and-manageable-safety-profile-of-azenosertib-plus-paclitaxel-in-platinum-resistant-ovarian-cancer-at-asco-2026/2349725

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at...

https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/zentalis-pharmaceuticals-to-present-phase-1b-muir-trial-data-showing-encouraging-clinical-activity-and-manageable-safety-profile-of-azenosertib-plus-paclitaxel-in-platinum-resistant-ovarian-cancer-at-asco-2026/2349725